NCT03678883 2024-11-079-ING-41 in Patients with Advanced CancersActuate Therapeutics Inc.Phase 2 Active not recruiting350 enrolled
NCT02982486 2017-11-01A Phase II of Nivolumab Plus Ipilimumab in Non-resectable Sarcoma and Endometrial CarcinomaAssaf-Harofeh Medical CenterPhase 2 Unknown60 enrolled